Alzheimer's Disease Long-term Follow-up Study (ALF Study)
NCT ID: NCT00165724
Last Updated: 2021-12-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
114 participants
INTERVENTIONAL
2004-06-30
2006-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Donepezil Hydrochloride
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of dementia according to DSM-IV
* Diagnosis of probable AD as defined by NINCDS-ADRDA criteria
* Mild to moderate AD at baseline, as defined by MMSE score of 10 to 26
* Patients were generally healthy and ambulatory or ambulatory aided
* Patients did not take acetylcholinesterase inhibitor 4 weeks before screening
* Patients have useful MRI results 3 months before screening
Exclusion
* If they have evidence of TIA or major infarction
* Epilepsy patients
* If they have evidence of other degenerative or psychiatric disorder, other serious disorder, alcoholism or drug abuse
* If they sensitive to acetylcholinesterase
* If they taken concomitant medication which were not allowed
40 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eisai Korea Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jiheed Mun
Role: STUDY_DIRECTOR
Eisai Korea Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bobath Memorial Hospital
Bundang, , South Korea
Bundang Seoul National University Hospital
Bundang, , South Korea
Changwon Fatima Hospital
Changwon, , South Korea
Yeungnam University Hospital
Daegu, , South Korea
Inha University Hospital
Incheon, , South Korea
Catholic University Hospital
Seoul, , South Korea
Eulji University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EKI-1002
Identifier Type: -
Identifier Source: org_study_id